Pathologic findings and clinical outcome of patients undergoing retroperitonial lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors

Cancer

Volumn 109, Issue 3, 2007, Pages 528-535

  Eggener, Scott E ^a   Carver, Brett S ^a   Loeb, Stacy ^b   Kondagunta, G Varuni ^a   Bosl, George J ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Metastatic; Retroperitoneal lymph node dissection; Salvage therapy; Testicular neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; TAXANE DERIVATIVE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; FIBROSIS; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; TERATOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RETROPERITONEAL NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TERATOMA; TESTICULAR NEOPLASMS;

EID: 33846675812     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22440     Document Type: Article

References (16)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337:242-253.
2. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23:6549-6555.
3. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15:2559-2563.
4. Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18:1173-1180.
5. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993;11:1294-1299.
6. Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668-1676.
7. Rick O, Bokemeyer C, Weinknecht S, et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2004;22:3713-3719.
8. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol. 1995;13:1170-1176.
9. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594-603.
10. Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998;16:65-71.
11. Donohue JP, Rowland RG. The role of surgery in advanced testicular cancer. Cancer. 1984;54(11 Suppl):2716-2721.
12. Steyerberg EW, Gerl A, Fossa SD, et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol. 1998;16:269-274.
13. Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer. 1982;50:1629-1635.
14. Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;159:133-138.
15. Beck SD, Patel MI, Sheinfeld J. Tumor marker levels in postchemotherapy cystic masses: clinical implications for patients with germ cell tumors. J Urol. 2004;171:168-171.
16. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993;11:324-329.